Literature DB >> 15326230

Surgical and hardware complications of subthalamic stimulation: a series of 160 procedures.

Kelly E Lyons1, Steven B Wilkinson, John Overman, Rajesh Pahwa.   

Abstract

OBJECTIVE: To assess the surgical and hardware complications in a series of 81 consecutive patients undergoing subthalamic (STN) deep brain stimulation (DBS) for Parkinson disease (PD).
METHODS: The authors prospectively documented surgical and hardware complications occurring at the time of surgery and at subsequent neurologic and surgical evaluations for an average of 17 months, ranging from 1 to 54 months.
RESULTS: No patient had a serious surgical complication resulting in death or permanent neurologic deficit. One patient had an intracranial hemorrhage but with no permanent deficit. In follow-up, 2.5% had infections requiring system removal, 3.7% had infections requiring implantable pulse generator (IPG) removal, 12.5% had misplaced leads, and 26.2% had hardware complications including lead migration, lead fracture, extension erosion, extension fracture, and IPG malfunction.
CONCLUSION: Serious complications leading to permanent neurologic deficit are rare after STN DBS for advanced PD. However, long-term follow-up demonstrated that hardware complications are relatively common, having occurred in approximately 26% of these patients.

Entities:  

Mesh:

Year:  2004        PMID: 15326230     DOI: 10.1212/01.wnl.0000134650.91974.1a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  49 in total

Review 1.  High frequency deep brain stimulation of the subthalamic nucleus versus continuous subcutaneous apomorphine infusion therapy: a review.

Authors:  R Carron; V Fraix; C Maineri; E Seigneuret; B Piallat; P Krack; P Pollak; A L Benabid; Stéphan Chabardès
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

2.  Deep brain stimulation in Parkinson's disease.

Authors:  S J Groiss; L Wojtecki; M Südmeyer; A Schnitzler
Journal:  Ther Adv Neurol Disord       Date:  2009-11       Impact factor: 6.570

Review 3.  What is the best treatment for fluctuating Parkinson's disease: continuous drug delivery or deep brain stimulation of the subthalamic nucleus?

Authors:  Rüdiger Hilker; Angelo Antonini; Per Odin
Journal:  J Neural Transm (Vienna)       Date:  2010-12-25       Impact factor: 3.575

Review 4.  Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases.

Authors:  Michael G Erkkinen; Mee-Ohk Kim; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-04-02       Impact factor: 10.005

5.  Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease.

Authors:  V Fraix; J-L Houeto; C Lagrange; C Le Pen; P Krystkowiak; D Guehl; C Ardouin; M-L Welter; F Maurel; L Defebvre; A Rougier; A-L Benabid; V Mesnage; M Ligier; S Blond; P Burbaud; B Bioulac; A Destée; P Cornu; P Pollak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-04       Impact factor: 10.154

6.  Intracranial delivery of stem cells.

Authors:  Keith W Muir; John Sinden; Erik Miljan; Laurence Dunn
Journal:  Transl Stroke Res       Date:  2011-07-26       Impact factor: 6.829

Review 7.  Deep brain stimulation.

Authors:  Joel S Perlmutter; Jonathan W Mink
Journal:  Annu Rev Neurosci       Date:  2006       Impact factor: 12.449

8.  Placement of the Internal Pulse Generator for Deep Brain Stimulation in the Upper Back to Prevent Fracture of the Extension Wire due to Generator Rotation: Case Report.

Authors:  Ankur Garg; Avinash L Mohan; P Charles Garell
Journal:  Parkinsons Dis       Date:  2010-02-08

9.  Delayed cerebritis after bilateral stereotactic implantation of globus pallidus interna electrodes for treatment of dystonia.

Authors:  Pawel P Jankowski; Stephanie Lessig; Andrew D Nguyen; David Barba
Journal:  BMJ Case Rep       Date:  2013-02-01

Review 10.  Towards a Better Treatment Option for Parkinson's Disease: A Review of Adult Neurogenesis.

Authors:  Parisa Farzanehfar
Journal:  Neurochem Res       Date:  2016-09-10       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.